newsfilter
← Latest News
GlobeNewswire·

Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments Announced plans to explore CE